PUR0200
Chronic Obstructive Pulmonary Disease (COPD)
PreclinicalActive
Key Facts
About Pulmatrix
Pulmatrix is a clinical-stage biotech focused on developing inhaled therapeutics for serious pulmonary and systemic diseases using its proprietary iSPERSE™ dry powder delivery platform. Its strategy centers on reformulating known drug molecules for inhalation to create new products with potential advantages in speed of onset, efficacy, and patient convenience. Key achievements include advancing its lead candidate, PUR3100 for acute migraine, into Phase 2 clinical development and building a diverse pipeline of 13 candidates. The company aims to leverage its versatile platform through internal development and potential partnerships.
View full company profileTherapeutic Areas
Other Chronic Obstructive Pulmonary Disease (COPD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Dupixent (dupilumab) | Regeneron | Phase 3 |
| REGEND001 | Regend | Phase 1 |
| COPD Trial | Well Pharma Medical Research | Not Specified |
| AN01 | AirNexis Therapeutics | Phase 2 |
| COPD Diagnostic/Prognostic Test | Oxford Cancer Analytics | Pre-clinical |
| SMS Cell Therapy | SMSbiotech | Phase 1b |
| dNerva Lung Denervation System / Targeted Lung Denervation (TLD) | Nuvaira | Phase 3 |
| LBP for COPD | Alveolus Bio | Preclinical |
| AstraZeneca Collaboration Programs | Ethris | Discovery/Pre-clinical |
| COPD Phenotyping & Progression Biomarkers | Thirona | Commercial/Validation |
| TEZSPIRE (tezepelumab) | Amgen | Phase 3 |
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |